Critical Analysis: OSRAM Licht (OTCMKTS:OSAGF) versus SWEDISH ORPHAN/S (OTCMKTS:SWTUY)

Profitability

This table compares OSRAM Licht and SWEDISH ORPHAN/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSRAM Licht	-22.92%	0.36%	0.06%
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%

Volatility & Risk

OSRAM Licht has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, SWEDISH ORPHAN/S has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Valuation and Earnings

This table compares OSRAM Licht and SWEDISH ORPHAN/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSRAM Licht	$3.71 billion	1.36	-$850.62 million	($1.19)	-44.96
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76

SWEDISH ORPHAN/S has lower revenue, but higher earnings than OSRAM Licht. OSRAM Licht is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.

Summary

SWEDISH ORPHAN/S beats OSRAM Licht on 8 of the 9 factors compared between the two stocks.

About OSRAM Licht

OSRAM Licht AG provides various lighting products and solutions worldwide. It operates through three segments: Opto Semiconductors, Automotive, and Digital. The company was formerly known as Kyros A AG and changed its name to OSRAM Licht AG in November 2012. OSRAM Licht AG was incorporated in 2012 and is headquartered in Munich, Germany. OSRAM Licht AG operates as a subsidiary of ams-OSRAM AG.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.